Q3 Earnings Forecast for PBH Issued By DA Davidson

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Research analysts at DA Davidson issued their Q3 2025 earnings estimates for Prestige Consumer Healthcare in a research report issued to clients and investors on Monday, November 11th. DA Davidson analyst L. Weiser anticipates that the company will post earnings per share of $1.16 for the quarter. DA Davidson has a “Buy” rating and a $95.00 price objective on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.44 per share. DA Davidson also issued estimates for Prestige Consumer Healthcare’s FY2025 earnings at $4.46 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. During the same quarter in the previous year, the company posted $1.07 EPS. Prestige Consumer Healthcare’s quarterly revenue was down .9% compared to the same quarter last year.

Separately, Jefferies Financial Group reaffirmed a “hold” rating and set a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and an average price target of $94.20.

Prestige Consumer Healthcare Stock Down 0.0 %

Shares of NYSE PBH opened at $81.71 on Tuesday. Prestige Consumer Healthcare has a 1 year low of $56.61 and a 1 year high of $82.82. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 1.90. The firm has a market cap of $4.04 billion, a PE ratio of 19.88, a price-to-earnings-growth ratio of 2.27 and a beta of 0.47. The company has a 50 day simple moving average of $72.69 and a 200 day simple moving average of $69.92.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently modified their holdings of PBH. Cerity Partners LLC boosted its stake in Prestige Consumer Healthcare by 103.9% during the third quarter. Cerity Partners LLC now owns 6,347 shares of the company’s stock worth $458,000 after acquiring an additional 3,234 shares in the last quarter. Citigroup Inc. boosted its position in shares of Prestige Consumer Healthcare by 66.6% during the 3rd quarter. Citigroup Inc. now owns 76,772 shares of the company’s stock worth $5,535,000 after purchasing an additional 30,677 shares in the last quarter. Eagle Asset Management Inc. grew its stake in shares of Prestige Consumer Healthcare by 0.7% in the 3rd quarter. Eagle Asset Management Inc. now owns 434,514 shares of the company’s stock valued at $31,328,000 after buying an additional 3,227 shares during the period. Intech Investment Management LLC bought a new stake in Prestige Consumer Healthcare in the 3rd quarter valued at about $620,000. Finally, Quest Partners LLC raised its stake in Prestige Consumer Healthcare by 2,582.0% during the 3rd quarter. Quest Partners LLC now owns 11,774 shares of the company’s stock worth $849,000 after buying an additional 11,335 shares during the period. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.